A phase Ib/IIa trial to evaluate the safety and efficacy of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced NSCLC

被引：0
|
作者：
Wu, Chunjiao
Lv, Dongqing
Cui, Jiuwei
Wang, Zhen
Zhao, Hui
Duan, Huaxin
Duan, Ping
Yin, Yongmei
Pan, Yueyin
Liu, Fu-Nan
Kong, Chuize
Zhang, Jian
Li, Yongsheng
Han, Xinpeng
Liu, Baogang
He, Lijie
Qin, Zhiquan
Wu, Tao
Ji, Mei
Cheng, Ying
机构：
[1] Jilin Canc Hosp, Dept Oncol, Phase Ward 1, Changchun, Jilin, Peoples R China
[2] Taizhou Hosp Zhejiang Prov, Taizhou, Peoples R China
[3] First Hosp Jilin Univ, Dept Oncol, Changchun, Peoples R China
[4] Linyi Canc Hosp, Linyi, Shandong, Peoples R China
[5] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 6, Dept Internal Oncol, Shanghai, Peoples R China
[6] Hunan Normal Univ, Key Lab Study & Discovery Small Targeted Mol Huna, Hunan Prov Peoples Hosp, Dept Oncol,Affiliated Hosp Hunan Normal Univ 1, Changsha, Peoples R China
[7] Chengdu Integrated TCM & Western Med Hosp, Chengdu, Peoples R China
[8] Jiangsu Prov Hosp, Nanjing, Peoples R China
[9] Anhui Prov Hosp, Hefei, Peoples R China
[10] China Med Univ, Hosp 1, Shenyang, Peoples R China
[11] Southern Med Univ, Zhujiang Hosp, Guangzhou, Peoples R China
[12] Chongqing Univ Canc Hosp, Phase Clin Trial Ctr 1, Chongqing, Peoples R China
[13] Xian Int Med Ctr Hosp, Xian, Peoples R China
[14] Harbin Med Univ Canc Hosp, Harbin, Peoples R China
[15] Peoples Hosp Liaoning Prov, Shenyang, Peoples R China
[16] Zhejiang Prov Peoples Hosp, Hangzhou, Peoples R China
[17] First Peoples Hosp Changde, Changde, Peoples R China
[18] First Peoples Hosp Changzhou, Changzhou, Jiangsu, Peoples R China
[19] Jilin Canc Hosp, Dept Oncol, Changchun, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8533
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase Ib/IIa safety and efficacy of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced solid tumors
    Guo, Ye
    Guo, Jun
    Cheng, Ying
    Wang, Zhen
    Li, Yongsheng
    Lv, Dongqing
    Yin, Yongmei
    Li, Guiling
    Wu, Lingying
    Huang, Yi
    Wei, Shuqing
    Shen, Lin
    Duan, Huaxin
    Cui, Jiuwei
    Luo, Hong
    Li, Xiumin
    Nan, Kejun
    Wang, Chunyan
    Luo, Su-Xia
    Liu, Ruonan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] A phase Ib/IIa trial to evaluate the safety and efficacy of PM8002/ BNT327, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced renal cell carcinoma
    Sheng, X.
    Luo, H.
    Kong, C.
    Liu, F.
    Wei, S.
    Wang, Z.
    Guo, Y.
    Yin, Y.
    Zhao, H.
    Li, G.
    Wu, B.
    Li, Y.
    Nan, K.
    Ke, M.
    Wu, T.
    Zhang, J.
    Wang, Z.
    Li, X.
    Lei, K.
    Guo, J.
    ANNALS OF ONCOLOGY, 2024, 35 : S1014 - S1014
  • [3] PHASE I SAFETY AND PRELIMINARY EFFICACY OF PM8002 IN SUBJECTS WITH ADVANCED SOLID TUMORS, A BISPECIFIC ANTIBODY TARGETING PD-L1 AND VEGF-A
    Guo, Ye
    Luo, Suxia
    Qin, Yanru
    Yin, Yongmei
    Li, Guiling
    Wang, Jingfen
    Li, Yongsheng
    Guo, Jun
    Zhang, Feng
    Huang, Yi
    Luo, Hong
    Lv, Dongqing
    Ying, Cheng
    Wang, Chunyan
    Chou, Chuan-Chu
    Gong, Chundan
    Chang, Ruixia
    Liu, Jing
    Hu, Guoqiang
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A758 - A758
  • [4] Efficacy and safety of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with solid tumors: Clinical data from advanced cervical cancer and platinum-resistant recurrent ovarian cancer cohorts
    Wu, Lingying
    Li, Guiling
    Wei, Shuqing
    Liu, Ruonan
    Cheng, Ying
    Li, Xiumin
    Li, Yongsheng
    Wang, Chunyan
    Yin, Yongmei
    Yang, Xiaofeng
    Lin, An
    Qin, Zhiquan
    Wu, Tao
    Shen, Lin
    Huang, Yi
    Nan, Kejun
    Duan, Ping
    Cui, Jiuwei
    Zhang, Jian
    Qin, Yanru
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] A Phase Ib/II Study to Assess the Safety and Efficacy of PM8002 (Anti-PD-L1 x VEGF-A Bispecific Antibody) in Combination with Nab-Paclitaxel for First Line Treatment of Locally Advanced or Metastatic Triple-Negative Breast Cancer
    Wu, Jiong
    Zhang, Jian
    Tong, Zhongsheng
    Zhang, Qingyuan
    Wang, Yong-Sheng
    Cheng, Qiao
    Chen, Xin
    Li, Zhihua
    Yin, Yongmei
    CANCER RESEARCH, 2024, 84 (09)
  • [6] A phase II safety and efficacy study of PM8002 (anti-PD-L1 x VEGF-A bispecific) combined with paclitaxel as a second-line therapy for small cell lung cancer (SCLC)
    Cheng, Y.
    Qin, Z.
    Meng, X.
    Xu, F.
    Wang, Y.
    Yao, Y.
    Fang, J.
    Zhao, Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S1062 - S1062
  • [7] Phase I/II safety and preliminary efficacy of PM1022, a bispecific antibody targeting PD-L1 and TIGIT, in patients with advanced solid tumors
    Xue, Junli
    Zhang, Yan
    Hu, Xudong
    Zhao, Wei
    Sun, Yuping
    Li, Qun
    Jin, Xiaoying
    Xue, Liqiong
    Ge, Xiaoxiao
    Lin, Fengjuan
    Tang, Wenbo
    Zhou, Jiuli
    Guo, Ye
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] Phase 1 trial safety and efficacy of ragistomig, a bispecific antibody targeting PD-L1 and 4-1BB, in advanced solid tumors
    Falchook, Gerald Steven
    LoRusso, Patricia
    Goldman, Jonathan W.
    El-Khoueiry, Anthony B.
    Tolcher, Anthony W.
    Xing, Yan
    Henry, Jason Timothy
    Keam, Bhumsuk
    Kim, Dong-Wan
    Kim, Tae-Yong
    Kim, Hye Ryun
    Hong, Min Hee
    Kim, Min Hwan
    Lee, Dae Ho
    Lee, SangMi
    Jeon, JuYeun
    Hayslip, John W.
    Xu, Cong
    Garon, Edward B.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [9] Phase I safety and preliminary efficacy of PM1003, a bispecific antibody targeting PD-L1 and 4-1BB, in patients with advanced solid tumors
    Xue, Junli
    Sun, Yuping
    Li, DaPeng
    Guo, Ye
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] Safety and efficacy of AK112, an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors in a phase I dose escalation study.
    Coward, Jermaine
    Mislang, Anna Rachelle Austria
    Frentzas, Sophia
    Lemech, Charlotte Rose
    Nagrial, Adnan
    Jin, Xiaoping
    Li, Baiyong
    Wang, Zhongmin Maxwell
    Kwek, Kon Yew
    Xia, Yu
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345